$Acumen Pharmaceuticals (ABOS.US)$ NEWS Acumen Pharmaceutica...
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma biomarkers indicating downstream effects on amyloid, pTau species, and synaptic markers.
Nearly all patients treated with high doses of sabirnetug showed reductions in plaque load after three doses.
Acumen Pharmaceuticals plans to initiate a Phase 2 trial of sabirnetug in the first half of 2024 and a Phase 1 bioavailability study for a subcutaneous dosing option in mid-2024.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma biomarkers indicating downstream effects on amyloid, pTau species, and synaptic markers.
Nearly all patients treated with high doses of sabirnetug showed reductions in plaque load after three doses.
Acumen Pharmaceuticals plans to initiate a Phase 2 trial of sabirnetug in the first half of 2024 and a Phase 1 bioavailability study for a subcutaneous dosing option in mid-2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
420Followers
64Following
2711Visitors
Follow